Literature DB >> 31516270

A Case of Sirolimus-Induced Interstitial Lung Disease After Liver Transplantation.

Narendra S Choudhary1, Sanjiv Saigal1, Amey Sonavane1, Ashish K Prakash2, Arvind Pandey3, Neeraj Saraf1, Arvinder S Soin1.   

Abstract

Mammalian target of rapamycin inhibitors (mTORis) are immunosuppression agents that are commonly used in solid organ transplantation. Available mTORis include sirolimus and everolimus. Interstitial lung disease (ILD) is an uncommon side effect of mTORis in liver transplantation. A high index of suspicion is needed, and timely intervention can reverse the disease. We present a case of sirolimus-induced ILD that improved after discontinuation of sirolimus.

Entities:  

Keywords:  HCC, hepatocellular carcinoma; ILD, Interstitial lung disease; dyspnea; interstitial lung disease; liver transplantation; mTORi, Mammalian target of rapamycin inhibitor; pulmonary; sirolimus

Year:  2018        PMID： 31516270      PMCID： PMC6728530          DOI： 10.1016/j.jceh.2018.09.005

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN： 0973-6883


  15 in total

1.  Sirolimus-induced interstitial pneumonitis.

Authors:  R N Bankar; S Kumar; A Köhnke
Journal:  J Postgrad Med       Date:  2006 Oct-Dec       Impact factor: 1.476

2.  Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.

Authors:  P Errasti; D Izquierdo; P Martín; M Errasti; F Slon; A Romero; F J Lavilla
Journal:  Transplant Proc       Date:  2010-10       Impact factor: 1.066

3.  Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors.

Authors:  C Morath; V Schwenger; D Ksoll-Rudek; C Sommerer; J Beimler; J Schmidt; M Zeier
Journal:  Transplant Proc       Date:  2007 Jan-Feb       Impact factor: 1.066

4.  [Pneumonitis caused by sirolimus: improvement after switching to everolimus].

Authors:  L Calle; C Tejada; C Lancho; A Mazuecos
Journal:  Nefrologia       Date:  2009       Impact factor: 2.033

5.  Resolution of sirolimus-induced pneumonitis after conversion to everolimus.

Authors:  B Rehm; F Keller; J Mayer; S Stracke
Journal:  Transplant Proc       Date:  2006-04       Impact factor: 1.066

Review 6.  Interstitial lung disease: the initial approach.

Authors:  Esam H Alhamad; Gregory P Cosgrove
Journal:  Med Clin North Am       Date:  2011-10-05       Impact factor: 5.456

7.  Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate.

Authors:  Luke Howard; Deepa Gopalan; Meryl Griffiths; Ravi Mahadeva
Journal:  Chest       Date:  2006-06       Impact factor: 9.410

8.  Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients.

Authors:  Sean Garrean; Malek G Massad; Michael Tshibaka; Ziad Hanhan; Amitra E Caines; Enrico Benedetti
Journal:  Clin Transplant       Date:  2005-10       Impact factor: 2.863

9.  Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.

Authors:  E Morelon; M Stern; D Israël-Biet; J M Correas; C Danel; M F Mamzer-Bruneel; M N Peraldi; H Kreis
Journal:  Transplantation       Date:  2001-09-15       Impact factor: 4.939

10.  Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center.

Authors:  A Rodríguez-Moreno; N Ridao; P García-Ledesma; N Calvo; I Pérez-Flores; M Marques; A Barrientos; A I Sánchez-Fructuoso
Journal:  Transplant Proc       Date:  2009 Jul-Aug       Impact factor: 1.066
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.